Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02 2019 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers for patient enrichment,
today announced that Richard Murray, Ph.D., chief executive officer
and president of Jounce, will present at the 37th Annual J.P.
Morgan Healthcare Conference on Wednesday, January 9, 2019 at 4:00
PM PT (7:00 PM ET) in San Francisco. Following the presentation,
management will participate in a question and answer session at
4:30 PM PT (7:30 PM ET).
A live webcast of the presentation will be available by visiting
“Events and Presentations” in the Investors and Media section of
Jounce’s website at www.jouncetx.com. A replay of the webcast will
be archived for 30 days following the presentation.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within the
human tumor microenvironment (TME) to prioritize targets, and then
identifies related biomarkers designed to match the right
immunotherapy to the right patient. Jounce has three
development-stage programs: its lead product candidate currently in
clinical trials, JTX-2011, a monoclonal antibody that binds to and
activates ICOS; JTX-4014, a monoclonal antibody that binds to PD-1
to be used in combination with its pipeline of future product
candidates; and JTX-8064, a monoclonal antibody that binds to
Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) that is
currently in the IND-enabling phase. For more information, please
visit www.jouncetx.com.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Media Contact:Gina NugentThe Yates Network(617)
460-3579gina@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024